Core Points - The document outlines the management system for the resignation of directors and senior management at Shouyao Holdings (Beijing) Co., Ltd, aiming to ensure stability in corporate governance and protect the rights of shareholders [1][2][3] Chapter Summaries Chapter 1: General Principles - The system is established in accordance with relevant laws and regulations, including the Company Law and Securities Law, to ensure compliance and protect shareholder interests [1] - It applies to directors and senior management resigning for various reasons, including term expiration and voluntary resignation [2] Chapter 2: Resignation Circumstances and Effectiveness - Directors and senior management can resign before their term ends by submitting a written resignation report, which takes effect upon receipt by the company [2] - If a director resigns and the board falls below the legal minimum number of members, the original director must continue to fulfill their duties until a new director is elected [2][3] Chapter 3: Responsibilities and Obligations upon Resignation - Resigning directors and senior management must complete all handover procedures within five working days after leaving [5] - Confidentiality obligations regarding company secrets remain in effect after resignation until the information becomes public [5] - Any public commitments made during their tenure must still be honored, and failure to do so may result in compensation claims from the company [5][6] Chapter 4: Accountability Mechanism - The board of directors is responsible for pursuing accountability against resigning directors and senior management who violate laws or company regulations, including potential criminal referrals for serious violations [7] - Resigning individuals can appeal the board's decisions regarding accountability within a specified timeframe [7] Chapter 5: Supplementary Provisions - The document clarifies that its terms align with the company's articles of association and relevant laws, and it is subject to amendments by the board of directors [8]

General Provisions - The purpose of the guidelines is to standardize the operation of Shouyao Holdings (Beijing) Co., Ltd. and enhance the role of the board secretary [1] - The board secretary is a senior management position responsible for adhering to laws, regulations, and the company's articles of association [1] Appointment and Qualifications - The board secretary must possess good professional ethics, necessary financial, management, and legal knowledge, and relevant work experience [2] - Individuals with certain disqualifying conditions, such as recent administrative penalties from the China Securities Regulatory Commission, cannot serve as board secretary [2][3] Responsibilities and Authority - The board secretary is responsible for information disclosure, managing investor relations, and ensuring compliance with relevant regulations [4][5] - The board secretary must provide consultation and advice for major decision-making and ensure adherence to procedures during board meetings [6][7] Legal Responsibilities - The board secretary has a duty of integrity and diligence, and must not misuse their position for personal gain or disclose company secrets [8][9] - Upon termination of their position, the board secretary must ensure proper handover of documents and responsibilities [9][10] Miscellaneous - The guidelines will take effect upon approval by the board and will be subject to amendments as necessary [11][12]

Core Viewpoint - The document outlines the management measures for the shares held by directors and senior management of Shouyao Holdings (Beijing) Co., Ltd, emphasizing the regulations and procedures for share transactions to ensure compliance with relevant laws and regulations [1][8]. Summary by Sections Management of Shareholding - The shares held by directors and senior management include those registered in their names and those held through others' accounts, as well as shares in their credit accounts if engaged in margin trading [1]. - Directors and senior management are prohibited from short selling the company's shares [1]. Trading Restrictions - Directors and senior management cannot buy or sell company shares during specific periods, including 15 days before annual and semi-annual reports, 5 days before quarterly reports, and during significant events until disclosure [1]. - Shares cannot be transferred within one year of the company's stock listing or within six months after leaving the company [2]. Transfer Limits - The maximum shares that directors and senior management can transfer in a year is capped at 25% of their total holdings, with exceptions for certain circumstances [3]. - Newly acquired shares can be transferred at a rate of 25% in the year of acquisition, while limited shares count towards the next year's transferable amount [4]. Disclosure Requirements - Directors and senior management must report and disclose their share transfer plans to the Shanghai Stock Exchange 15 trading days before selling [10]. - After completing a transfer, they must report to the exchange within two trading days [5]. Compliance and Reporting - Any changes in shareholding must be reported within two trading days, including details of the change [12]. - Violations of securities laws regarding share transactions result in the company reclaiming profits from the directors and senior management [6]. Additional Provisions - The document states that if the company's articles of association impose stricter conditions than these measures, those conditions must be followed [9]. - The board of directors is responsible for interpreting and updating these measures as necessary [19].

证券代码：688197 证券简称：首药控股 公告编号：2025-019 首药控股（北京）股份有限公司 关于第二届监事会第九次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 首药控股（北京）股份有限公司（以下称"公司"或"首药控股"）第二届监 事会第九次会议于2025年8月26日在公司会议室以现场方式召开。本次会议的通 知于2025年8月15日由专人送达全体监事。会议应出席监事3人，实际出席监事3 人。会议由监事会主席刘志华先生主持。会议的召集及召开程序符合《公司法》 和《公司章程》的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （二）审议通过了《关于公司<2025 年半年度募集资金存放与实际使用情 况的专项报告>的议案》 表决结果：3 票赞成；0 票弃权；0 票反对。 经审核，监事会认为：公司 2025 年半年度募集资金存放与实际使用符合中 国证监会《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》《公司章程》以及公司《募集资 ...

Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025, scheduled for September 15, 2025, at 10:00 AM in Beijing [5][6]. - The meeting will address several key proposals, including the reappointment of the accounting firm for the 2025 financial year and amendments to the company's articles of association [7][14]. Meeting Procedures - Attendees must arrive 30 minutes early for registration and identification verification [1]. - Only shareholders, their proxies, and invited guests are allowed to enter the meeting venue [1][2]. - Shareholders have the right to speak, ask questions, and vote, but must register their intent to speak beforehand [2][3]. - Voting will be conducted through a combination of on-site and online methods, with each share carrying one vote [3][5]. Agenda Items - The agenda includes the reappointment of Tianjian Accounting Firm as the auditor for the 2025 financial year, with a proposed fee of 300,000 yuan, unchanged from the previous year [8][11]. - A proposal to change the registered address of the company and to abolish the supervisory board is also on the agenda [14][15]. - Amendments to the company's articles of association will be discussed to align with recent legal updates and improve governance [14][15]. Voting and Decision-Making - The meeting will utilize a named voting method, where shareholders can choose to agree, disagree, or abstain from each proposal [3]. - The results of the voting will be announced after the meeting, combining both on-site and online votes [3][5]. - The proposals require a two-thirds majority from the voting shareholders to pass [16].

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 15, 2025, at 10:00 AM in the conference room of the company located at No. 15, Yuquan Huigu Technology Park, Minzhuang Road, Haidian District, Beijing [1][3] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's network voting system [1][3] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system from 9:15 AM to 3:00 PM on the day of the meeting [1][4] - Specific voting procedures apply to margin trading, transfer, and other related accounts as per the regulations of the Shanghai Stock Exchange [2] Agenda Items - The meeting will review several non-cumulative voting proposals, including: - Renewal of the financial statement and internal control audit institution for 2025 - Change of registered address, cancellation of the supervisory board, and amendments to the Articles of Association - Revisions to various management rules, including related party transactions and external guarantees [2][4][8] Attendance and Registration - Shareholders registered by the close of trading on September 9, 2025, are eligible to attend the meeting [5] - Registration will take place on September 11, 2025, with specific documentation required for attendance [5][6] Additional Information - The company will provide a reminder service for shareholders to facilitate attendance and voting [7] - Contact details for inquiries regarding the meeting are provided, including an email address and phone number [7]

证券代码：688197 证券简称：首药控股 公告编号：2025-018 首药控股（北京）股份有限公司 关于第二届董事会第十次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 首药控股（北京）股份有限公司（以下称"公司"）第二届董事会第十次会 议于2025年8月26日在公司会议室以现场方式召开。本次会议的通知于2025年8 月15日以专人送达、电子邮件等方式送达全体董事。会议应出席董事7人，实际 出席董事7人，全体监事、董事会秘书现场列席会议。会议由董事长李文军先生 主持。会议召集及召开程序符合《公司法》和《公司章程》的有关规定，会议 决议合法、有效。 二、董事会会议审议情况 （一）审议通过了《关于公司<2025 年半年度报告>及其摘要的议案》 表决结果：7 票赞成；0 票弃权；0 票反对。 公 司 《 2025 年 半 年 度 报 告 》 详 见 同 日 披 露 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn，下同）的公告。 公司《2025 年半年度报告摘要》 ...

首药控股（北京）股份有限公司2025 年半年度报告 公司代码：688197 公司简称：首药控股 首药控股（北京）股份有限公司 2025 年半年度报告 2025 年 8 月 1 / 161 首药控股（北京）股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已于本报告第三节"管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生 不利影响的风险因素，敬请投资者予以关注并注意投资风险。 三、 公司全体董事出席董事会会议。 九、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 十一、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 四、 本半年度报告未经审计。 五、 公司负责人李文军、主管会计工作负责人王亚杰及会计机构负责人（会计主管人员）王亚 杰声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司无 2025 年半年度利润分 ...

首药控股（北京）股份有限公司 董事会战略委员会实施细则 首药控股（北京）股份有限公司 董事会战略委员会实施细则 第一章 总 则 第一条 为适应首药控股（北京）股份有限公司（以下称"公司"）战略发展 需要，增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加强决策 科学性，提高重大投资决策的效益和决策的质量，完善公司治理结构，根据《中 华人民共和国公司法》和《首药控股（北京）股份有限公司章程》（以下称"公司 章程"）等规定，制定《董事会战略委员会实施细则》（以下称"本细则"）。 第二条 董事会战略委员会是董事会按照股东会决议设立的专门工作机构， 主要负责对公司长期发展战略和重大投资决策进行研究，并向董事会提出建议。 第二章 人员组成 第三条 战略委员会由三名公司董事组成。 第四条 战略委员会委员由公司董事长、过半数独立董事或者全体董事的三 分之一提名，并由董事会以全体董事的过半数选举产生。 第五条 战略委员会设主任委员一名，由董事长担任，负责召集和主持委员 会工作。 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，自动失去委员资格，并由委员会根据上述 ...

首药控股（北京）股份有限公司 募集资金管理办法 首药控股（北京）股份有限公司 募集资金管理办法 第一章 总 则 第一条 为规范首药控股（北京）股份有限公司（以下称"公司"）募集资金 的管理和使用，保护投资者的权益，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规 范运作》等法律、部门规章、规范性文件及《首药控股（北京）股份有限公司章 程》（以下称"《公司章程》"）的有关规定，特制定本办法。 第二条 本办法所称募集资金，是指公司通过公开发行证券（包括首次公开 发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券 等）以及非公开发行证券向投资者募集并用于特定用途的资金，但不包括公司实 施股权激励计划募集的资金。 第三条 公司应当建立并完善募集资金存放、管理、使用、改变用途、监督 和责任追究的内部控制制度，明确募集资金使用的分级审批权限、决策程序、风 险控制措施及信息披露要求，规范使用募集资金。 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防范投资风 ...